Clinical Trial

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

Study acronym: Brilliance NT2
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
Protocol Amendment History 5 changes
notable Trial sites expanded: 19 -> 28 locations 2026-08-08
notable Trial sites expanded: 15 -> 19 locations 2026-07-03
notable Trial sites expanded: 8 -> 15 locations 2026-06-11
notable Trial sites expanded: 2 -> 8 locations 2026-05-07
critical Recruitment opened 2026-04-22
Trial Details
NCT Number NCT07502443
Lead Sponsor Alkermes, Inc.
Conditions Narcolepsy Type 2
Enrollment 176 participants
Start Date 2026-04-22
Primary Completion 2027-05 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-07